Prior to this approval.

Prior to this approval, Vectibix got received conditional acceptance in the EU as monotherapy. The monotherapy indication was also further revised to convey that Vectibix is definitely indicated for the treating patients with wild-type KRAS mCRC as monotherapy after failing of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens ead . Colorectal cancer may be the second most common malignancy in women worldwide and the 3rd most common cancer in men. 1 Approximately.

read more

1, 2013, and will develop and launch five Stage 3 molecules, starting with evolocumab . In China, the jv with Betta Pharma Co. Ltd. In emerging development markets, Amgen repurchased rights to NEUPOGEN and Neulasta from Roche. Effective Jan. 1, 2014, Amgen will presume responsibility for the products in markets outside the U.S. And Europe with annual sales of approximately $200 million. About Amgen Amgen is committed to unlocking the potential of biology for individuals suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.

Other entries from category "medicine":

Tag Cloud